Anti-TNF Agents as Therapeutic Choice in Immune-Mediated Inflammatory Diseases: Focus on Adalimumab

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation

(2014) K Malottki et al.   HEALTH TECHNOLOGY ASSESSMENT

Safety of Anti-TNF Agents During Pregnancy and Breastfeeding in Women With Inflammatory Bowel Disease

(2013) Javier P Gisbert et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries

(2013) Jakub Zavada et al.   ANNALS OF THE RHEUMATIC DISEASES

Adalimumab in active ulcerative colitis: A “real-life” observational study

(2013) Alessandro Armuzzi et al.   DIGESTIVE AND LIVER DISEASE

Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis

(2013) Pauline A. van Schouwenburg et al.   Nature Reviews Rheumatology

Impact of biologic therapy on functional status in patients with rheumatoid arthritis--a meta-analysis

(2013) J. Callhoff et al.   RHEUMATOLOGY

Biologic treatment response among adults with juvenile idiopathic arthritis: results from the British Society for Rheumatology Biologics Register

(2013) Flora McErlane et al.   RHEUMATOLOGY

Predictors for the 5-year risk of serious infections in patients with rheumatoid arthritis treated with anti-tumour necrosis factor therapy: a cohort study in the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry

(2013) S. A. A. van Dartel et al.   RHEUMATOLOGY

The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases

(2013) M. Jani et al.   RHEUMATOLOGY

Profile of certolizumab and its potential in the treatment of psoriatic arthritis

(2013) Maria Sole Chimenti et al.   Drug Design Development and Therapy

One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2

(2012) W. J. Sandborn et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry

(2012) Gary R Lichtenstein et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Impact of tumour necrosis factor inhibitor treatment on radiographic progression in rheumatoid arthritis patients in clinical practice: results from the nationwide Danish DANBIO registry

(2012) Lykke Midtbøll Ørnbjerg et al.   ANNALS OF THE RHEUMATIC DISEASES

Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry

(2012) Sanne A A van Dartel et al.   ANNALS OF THE RHEUMATIC DISEASES

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011

(2012) D E Furst et al.   ANNALS OF THE RHEUMATIC DISEASES

A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry

(2012) Jeffrey D Greenberg et al.   ANNALS OF THE RHEUMATIC DISEASES

Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study

(2012) Arthur Kavanaugh et al.   ANNALS OF THE RHEUMATIC DISEASES

Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept and infliximab in the GISEA registry

(2012) Fabiola Atzeni et al.   AUTOIMMUNITY REVIEWS

Tight control applied to the biological therapy of rheumatoid arthritis

(2012) Oscar Massimiliano Epis et al.   AUTOIMMUNITY REVIEWS

Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn's Disease: Data From the EXTEND Trial

(2012) Paul Rutgeerts et al.   GASTROENTEROLOGY

The interactions of therapeutic antibodies with Fc receptors

(2012) Marcello Albanesi et al.   IMMUNOLOGY LETTERS

Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis

(2012) María José Morales-Lara et al.   JOINT BONE SPINE

Meta-analysis of clinical and radiological efficacy of biologics in rheumatoid arthritis patients naive or inadequately responsive to methotrexate

(2012) Audrey Pierreisnard et al.   JOINT BONE SPINE

Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome

(2012) Orlando García-Bosch et al.   Journal of Crohns & Colitis

Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients

(2012) Filip Baert et al.   Journal of Crohns & Colitis

Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates through 3years for adalimumab-treated patients with early Crohn's disease

(2012) S. Schreiber et al.   Journal of Crohns & Colitis

Longterm Retention of Tumor Necrosis Factor-  Inhibitor Therapy in a Large Italian Cohort of Patients with Rheumatoid Arthritis from the GISEA Registry: An Appraisal of Predictors

(2012) F. IANNONE et al.   JOURNAL OF RHEUMATOLOGY

An observational, prospective study of monthly adalimumab therapy for disease maintenance in psoriasis patients: a possible new therapeutic option for good responders to the initial induction treatment

(2012) T. Taniguchi et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry

(2012) P. Gisondi et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Systematic Review and Meta-Analysis of the Efficacy and Safety of Existing TNF Blocking Agents in Treatment of Rheumatoid Arthritis

(2012) Kalle J. Aaltonen et al.   PLoS One

The prevalence of clinical remission in RA patients treated with anti-TNF: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry

(2012) Yvonne M. R. de Punder et al.   RHEUMATOLOGY

Wie früh würden wir Biologika wirklich einsetzen?

(2012) H.G. Nüßlein   ZEITSCHRIFT FUR RHEUMATOLOGIE

A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach

(2011) Susanne Schmitz et al.   ANNALS OF THE RHEUMATIC DISEASES

Anti-TNF therapy

(2011) Nishanthi Thalayasingam et al.   BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY

A Dose–Response Meta-Analysis for Quantifying Relative Efficacy of Biologics in Rheumatoid Arthritis

(2011) J W Mandema et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis

(2011) William J. Sandborn et al.   GASTROENTEROLOGY

Indirect comparison of biological treatments in refractory rheumatoid arthritis

(2011) M. Gallego-Galisteo et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Persistence with Anti-Tumor Necrosis Factor Therapies in Patients with Rheumatoid Arthritis: Observations from the RADIUS Registry

(2011) J. A. MARKENSON et al.   JOURNAL OF RHEUMATOLOGY

Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: Results from an open-label extension study for patients from REVEAL

(2011) Kenneth Gordon et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: data from a German noninterventional observational study

(2011) Stefan Kleinert et al.   RHEUMATOLOGY INTERNATIONAL

„Treat-to-Target“ (T2T) aus der Sicht der stationären Rheumatologie

(2011) H.-J. Lakomek et al.   ZEITSCHRIFT FUR RHEUMATOLOGIE

Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: Results from the Consortium of Rheumatology Researchers of North America registry

(2011) Daniel E. Furst et al.   ARTHRITIS CARE & RESEARCH

Efficacy of initial methotrexate monotherapy versus combination therapy with a biological agent in early rheumatoid arthritis: a meta-analysis of clinical and radiographic remission

(2010) B. Kuriya et al.   ANNALS OF THE RHEUMATIC DISEASES

Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA

(2010) J. L. Nam et al.   ANNALS OF THE RHEUMATIC DISEASES

No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register

(2010) Mark Lunt et al.   ARTHRITIS AND RHEUMATISM

How do patients with inflammatory bowel disease want their biological therapy administered?

(2010) Patrick B Allen et al.   BMC GASTROENTEROLOGY

Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy

(2010) K. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors

(2010) Devesh Mewar et al.   BRITISH JOURNAL OF PHARMACOLOGY

Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases

(2010) Peter C Taylor   CURRENT OPINION IN PHARMACOLOGY

The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in Inflammatory Bowel Disease☆

(2010) Ambrogio Orlando et al.   DIGESTIVE AND LIVER DISEASE

Effectiveness of Biologic Therapies for Rheumatoid Arthritis: An Indirect Comparisons Approach

(2010) Emily Beth Devine et al.   PHARMACOTHERAPY

Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries

(2010) X. Mariette et al.   RHEUMATOLOGY

BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies

(2010) T. Ding et al.   RHEUMATOLOGY

Anti-tumor necrosis factor therapy and cancer risk in patients with autoimmune disorders

(2010) Karen B. Onel et al.   ARTHRITIS CARE & RESEARCH

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)

(2009) W. G. Dixon et al.   ANNALS OF THE RHEUMATIC DISEASES

Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry

(2009) Merete Lund Hetland et al.   ARTHRITIS AND RHEUMATISM

What factors determine patients’ preference for tumour necrosis factor inhibitors in ankylosing spondylitis?

(2009) Dessy W. Fajri et al.   CLINICAL RHEUMATOLOGY

Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab

(2009) Waqqas Afif et al.   INFLAMMATORY BOWEL DISEASES

Retrospective analysis of systemic treatments for psoriasis patients attending a Psocare center in Florence. Relevance of biological drugs use and comorbidities

(2009) F Prignano et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Ocular and Systemic Autoimmunity after Successful Tumor-Infiltrating Lymphocyte Immunotherapy for Recurrent, Metastatic Melanoma

(2009) Steven Yeh et al.   OPHTHALMOLOGY

Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study)

(2009) S. Scarpato et al.   RHEUMATOLOGY

Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register

(2009) P. A. C. Lord et al.   RHEUMATOLOGY

Persistence with anti-tumor necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register

(2009) Amr A Saad et al.   ARTHRITIS RESEARCH & THERAPY

Impact of adalimumab on work participation in rheumatoid arthritis: comparison of an open-label extension study and a registry-based control group

(2008) M T Halpern et al.   ANNALS OF THE RHEUMATIC DISEASES

Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial

(2008) D van der Heijde et al.   ANNALS OF THE RHEUMATIC DISEASES

Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)

(2008) P J Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

Treatment of rheumatoid arthritis with anti-TNF-alpha agents: A reappraisal

(2008) Roberto Caporali et al.   AUTOIMMUNITY REVIEWS

Impact of Body Mass Index and Obesity on Clinical Response to Systemic Treatment for Psoriasis

(2008) Luigi Naldi et al.   DERMATOLOGY

Psocare: Italy Shows the Way in Postmarketing Studies

(2008) Tamar Nijsten et al.   DERMATOLOGY

Adalimumab with or without Methotrexate in Juvenile Rheumatoid Arthritis

(2008) Daniel J. Lovell et al.   NEW ENGLAND JOURNAL OF MEDICINE

The British Society for Rheumatology Biologics Register: 6 years on

(2008) K. L. Hyrich et al.   RHEUMATOLOGY

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

(2007) Alan Menter et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Tumor necrosis factor antagonist mechanisms of action: A comprehensive review

(2007) Daniel Tracey et al.   PHARMACOLOGY & THERAPEUTICS